SART1抗体;SART1 Antibody—艾普蒂

+ +

•  

   

     All lanes use the Antibody at 1:2K dilution for 1 hour at room temperature.    

  
  

SART1 antibodies target the SART1 (squamous cell carcinoma antigen recognized by T cells 1) protein, a dual-function molecule involved in mRNA splicing and tumor antigen presentation. The SART1 gene encodes two major isoforms: SART1-800 (nucleus-specific) and SART1-1025 (cytoplasm-specific). SART1-800 participates in pre-mRNA splicing as a component of the U4/U6.U5 tri-snRNP complex, while SART1-1025 is processed into peptides presented by HLA class I molecules on tumor cells, eliciting cytotoxic T lymphocyte (CTL) responses against cancers.

Overexpressed in various malignancies (e.g., squamous cell carcinomas of the head, neck, and esophagus), SART1 serves as a tumor-associated antigen, making it a target for cancer immunotherapy. Antibodies against SART1 are primarily used in research to detect protein expression/localization, study its role in mRNA processing, and evaluate its immunogenicity in tumor models. Clinically, SART1-derived peptides have been tested in vaccine trials to activate antitumor immunity. However, its dual role complicates therapeutic applications, as nuclear SART1-800 is essential for cell viability, whereas cytoplasmic SART1-1025 drives immune recognition. This functional dichotomy underscores the need for isoform-specific antibody tools to dissect SART1's contributions to both oncogenesis and immune surveillance.